Aurobindo Pharma gets to participate in PEPFAR

Aurobindo Pharma has received USFDA approval for Lamivudine, a key ARV in the treatment of AIDS. The move enables the company to participate in PEPFAR (President's Emergency Plan for Aids Relief), an initiative by US Government.

According to a Aurobindo Pharma release issued to the BSE, the company manufactures both API and formulation for Lamivudine, and has already filed several applications in the ARV segment with USFDA.

The company is fully vertically integrated in manufacturing APIs and formulations across most ARVs (NRTIs, NNRTIs and PIs) for the PEPFAR programme and hence well positioned as a very competitive player, the release said further.